The size of the North America Antibodies Market was valued at USD 63.55 Billion in 2023 and estimated to reach USD 114.26 Billion by the end of 2028, growing at a CAGR of 12.45 % during the forecast period.
The market for antibodies in North America is majorly driven by continuous development of innovative products, increased adoption rate to therapeutic antibodies in cost-sensitive markets, rise in chronic illnesses owing to population shift and rising longevity, rapid approval by regulatory authorities for breakthrough therapies, and adoption of diagnostic antibodies. Companies are adopting various strategies, like the expansion of product indications to sustain the dynamically growing market.
The antibodies market is a very fast-growing market in terms of research, and there is constant innovation in the field. Constant innovation of newer innovative products is therefore known to drive the demand in the market. Also, very cost-sensitive markets are now adapting to the therapeutic antibodies, increasing the demand for the antibodies.
The epidemiological transition from acute to chronic illnesses and increased life expectancy in North America has increased the demand for antibodies in the long run. The fertile environment for the new therapeutic antibodies, government policies are further helping the industry to flourish. The companies adapt to the changing market and orient their business plan and policies to help increase the antibodies sector.
The high cost of treatment and side effects associated with antibody treatment are the restraints that affect the market's growth.
Impact of COVID-19 on the North American antibodies market:
The COVID-19 epidemic has offered significant business prospects. Several pharmaceuticals are doing considerable R&D to create innovative vaccinations, treatment methods, and diagnostic kits for this pandemic. The need for research antibodies has risen considerably due to these intensive R&D operations to develop innovative vaccination and therapy methods. Moreover, several corporate and public entities are taking significant steps to assist the development of COVID-19 vaccines and treatments. As a result, the worldwide antibody market was extremely beneficial due to the vast range of applications for which it may be used.
This research report on the North American antibodies market has been segmented and sub-segmented into the following categories:
By Product Type:
By End User:
Geographically, in 2022, North America dominated the global antibodies market with a share of 39.7%. This is due to increased research in the domains of proteomics and genomics and the existence of major biopharmaceutical and biotechnology companies.
The market in North America is growing because of the rising incidence of cardiovascular disease, increased need for antibodies for research reproductivity, government investments in improving healthcare expenses, and increased development efforts to create better diagnostic therapy. Investing in medicines and improving healthcare infrastructure
These antibodies can be used to develop medicinal therapies and test immunoassays. Immunoassay tests are used to determine if a certain antigen or antibody is present in a patient's blood or other fluid samples. It's frequently utilized in novel drug development, drug monitoring, and food sample testing.
The Canadian antibodies market is also estimated to increase its market growth in the upcoming years with the government's help.
KEY MARKET PLAYERS:
A few promising companies in the North American antibodies market profiled in the report are Abbott Diagnostics, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and company, A.G. Scientific, Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, and AbbVie Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]